SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Rib-X Pharmaceuticals, Inc. Reports Additional Positive Delafloxacin Data at ICAAC, Including Performance Against New Objective Endpoints From FDA, From Its Completed Phase 2b Study in Patients With Acute Bacterial Skin and Skin Structure Infections